Total revenue from operations for the December quarter stood at Rs 8,154.85 crore, up 5.36% from Rs 7,740.19 crore in Q3 December 2018. Profit before tax declined 21.89% to Rs 1,351.33 crore in Q3 FY20 from Rs 1,730.11 crore in Q3 FY19. In Q3 FY20, EBITDA stood at Rs 1,725 crore with a resulting EBITDA margin of 21.5%. India sales stood at Rs 2,517 crore, growth of 13% over Q3 last year. US finished dosage sales at $ 350 million, decline of 3% over Q3 last year. Emerging markets sales at $195 million, down by 4% Q3 last year. Rest of World sales at $155...